Long-Lasting Supply : 240 capsules for 8 months of consistent health support
Dwarkanath P, Barzilay JR, Thomas T, et al
The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
In these cases, hydroxocobalamin or adenosylcobalamin may be better tolerated, as they provide B12 support without strongly stimulating methylation
Over the life of a vial, it adds up